Result: A total of 4.4% (20/460) of the sequences contained five different IN accessory mutations: -E157Q (2.39%), G163R/K (0.65%), Q95K (0.65%), T97A (0.43%), and G149A (0.22%).
Discussion: The other nonpolymorphic and polymorphic accessory mutations detected were G163R and T97A, which can contribute to a high-level resistance when occurring with Y143 and N155H major INSTI-resistance mutations.
Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.
PMID: 35300056
2022
Pharmacogenomics and personalized medicine
Abstract: Two patients have E138A and G163R mutations respectively and both could cause low-level resistance to RAL and EVG.
Result: A total of 12 polymorphic accessory mutations were detected, including E157Q (0.58%, 5/865), T97A (0.23%, 2/865), E138A (0.12%, 1/865), E157EQ (0.12%, 1/865), G163R (0.12%, 1 /865), Q95K (0.12%, 1/865), and S230R (0.12%, 1/865) (as shown in Figure 2).
Result: Among 12 IN-related polymorphic accessory mutations, only E138A, S230R and G163R mutations cause low-level resistance to PMID: 35274144
2022
The Journal of antimicrobial chemotherapy
Abstract: PBMC DNA deep sequencing performed some months later revealed mutations M184I (14.29%) and M230I (6.25%) in the reverse transcriptase and G163R (9.77%) and S230N (98.8%) in the integrase.
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
PMID: 34694877
2022
Antimicrobial agents and chemotherapy
Table: G163R
Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells.
Abstract: We designed DNA-vaccines against drug-resistant HIV-1 based on consensus clade A integrase (IN) resistant to raltegravir: IN_in_r1 (L74M/E92Q/V151I/N155H/G163R) or IN_in_r2 (E138K/G140S/Q148K) carrying D64V abrogating IN activity.
Method: Raltegravir-resistant IN_a variants with two patterns of primary resistance to RAL: L74M, E92Q, V151I, N155H, G163R (IN_a_r1) and PMID: 33800269
2021
International journal of environmental research and public health
Abstract: We identified the Q148HKR, G140S, Y143R, N155H, S147G, and E138EA major drug resistance mutations and the D232DN, T97TA, E157Q, G163GART accessory mutations.
Result: We also identified the resistance-accessory mutations D232DN, T97TA, E157Q, and G163GART (Figure 2B).
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
Introduction: Computational modelling of RAMs against INSTIs, across different HIV-1 subtypes compared to subtype B, showed that the presence of M50I in subtypes A and C, L74I in subtypes A and CRF02_AG, G163R in CRF01_AE, and V165I in subtypes F and CRF01_AE are associated with a lower genetic barrier to resistance in non-B clades.
High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.
PMID: 34453542
2021
The Journal of antimicrobial chemotherapy
Abstract: However, combinations of primary INSTI-resistance mutations such as E138A/G140A/G163R/Q148R or E138K/G140A/S147G/Q148K led to decreased susceptibility to both cabotegravir (fold change in EC50 values from 429 to 1000x) and bictegravir (60 to 100x), exhibiting a high degree of cross-resistance.
Abstract: RESULTS: HIV-1 IN-recombinant viruses harbouring single primary mutations (N155H or Y143R/S) or in combination with secondary INSTI mutations (T97A, M50
Characterizing HIV-1 Genetic Subtypes and Drug Resistance Mutations among Children, Adolescents and Pregnant Women in Sierra Leone.
Result: No PIs RAMs were observed, whereas three accessory INSTI-selected mutations T97A (n = 1), E157Q (n = 2), and G163R (n = 1), which have minimal effect on INSTI susceptibility, were observed in four pregnant women.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
PMID: 32675772
2020
Journal of acquired immune deficiency syndromes (1999)
Discussion: Interestingly, in 1 participant with baseline integrase substitutions N155N/H and G163G/R by proviral DNA genotype assay, only the integrase polymorphism mixture (V151V/I), which is not associated with dolutegravir resistance, was detected at virologic failure.
HIV mutation literature information.
PMID: 
2022
Viruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT